TSHA

Latest SEC Filings & News for TSHA

2 most recent filings and news items mentioning TSHA. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/TSHA/news?limit=20"

Pull TSHA filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

OfferingJun 25, 2026Neutral

Taysha Gene Therapies signs underwriting agreement for stock sale.

Taysha Gene Therapies agreed to sell 32.5 million shares of common stock and warrants to underwriters. The capital raising initiative is expected to provide liquidity to the company.

View filing at SEC.gov →

RegulatoryJun 22, 2026Positive

Taysha completes dosing in REVEAL pivotal trial for TSHA-102 Rett syndrome therapy

Taysha Gene Therapies completed enrollment of 17 patients in its REVEAL pivotal trial for TSHA-102, with 100% of Phase 1/2 Part A patients achieving developmental milestones and no serious adverse events reported. The company expects topline interim data and FDA feedback on BLA s

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.